Aims/hypothesis Diabetic dyslipidaemia contributes to the excess morbidity and mortality in
patients with type 2 diabetes. Exogenous glucagon-like peptide 1 (GLP-1) lowers …

Abstract Glucagon-like peptide 1 (GLP-1) is an incretin hormone responsible for
amplification of insulin secretion when nutrients are given orally, as opposed to …

Glucagon‐like peptide‐1 (7–36) amide (GLP‐1) is released from the gut into the circulation
after meals and is the most potent physiological insulinotropic hormone in man. In contrast to …

Abstract Background Glucagon-like peptide-1 (GLP-1) and its agonists are under
assessment in treatment of type 2 diabetes, by virtue of their antidiabetic actions, which …

Background & Aims: The gut-derived peptide glucagon-like peptide 2 (GLP-2) has been
suggested as a potential drug candidate for the treatment of various intestinal diseases …

Studies examining small groups of type 2-(NIDDM) diabetic patients have shown the
potential of glucagon-like peptide 1 (GLP-1) to normalize fasting hyperglycaemia. Patient …

GLP-1 (glucagon-like peptide-1), recently proposed as a new tool for the therapy of NIDDM
[1], is a natural occurring glucose-dependent insulinotropic peptide, with incretin …

Aims/hypothesis Glucagon-like peptide-1 (GLP-1) lowers glucose levels by potentiating
glucose-induced insulin secretion and inhibiting glucagon release. The question of whether …

We have previously shown that type 2 diabetic patients have decreased plasma
concentrations of glucagon-like peptide 1 (GLP-1) compared with healthy subjects after …

1. Glucagon-like peptide-1 (7-36) amide (GLP-1) is released into the circulation after meals
and is the most potent physiological insulinotropic hormone in man. GLP-1 has the …